Brodalumab
Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis[1][2].
Product Specifications
CAS Number
1174395-19-7
Product Name Alternative
AMG 827; KHK4827
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/brodalumab.html
Purity
99.18
Solubility
H2O
Smiles
[Brodalumab]
Molecular Weight
(144.06 kDa)
References & Citations
[1]Papp KA, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012 Mar 29;366 (13) :1181-9.|[2]Martin DA, et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther. 2013 Oct 25;15 (5) :R164.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS7029544-01 0.02 mg
Recombinant Synechocystis sp. Protein translocase subunit SecF (secF)
Sign In for Pricing
View Details MBS7029544-02 0.1 mg
Recombinant Synechocystis sp. Protein translocase subunit SecF (secF)
Sign In for Pricing
View Details MBS7029544-03 5x 0.1 mg
Recombinant Synechocystis sp. Protein translocase subunit SecF (secF)
Sign In for Pricing
View Details